Live news related to LAKEFRONT BIOTHER. stock (BE0003818359): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Belgian laboratory Galapagos announced on December 18 the results of two phase 3 studies evaluating its selective TYK2 inhibitor, GLPG3667. The trial …
Galapagos NV has announced new Phase 2 data on its therapeutic candidate GLPG5101 during the annual meeting of the American Society of Hematology.
The stock of Belgian biotech company Galapagos ended the session on Tuesday, October 21, with a sharp decline of 5.87%, closing at 27.88 euros. This d…
